DELRAY BEACH, Fla., Nov. 07, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Caregiver® non-contact, infrared thermometer exceeds industry laboratory standards for accuracy and showed a high level of agreement in a pediatric study. Caregiver, which uses TouchFree™ technology, eliminates the need to take oral or rectal temperatures, thus improving ease of use and patient comfort.
In a one-year pediatric validation study, temperature measurements were obtained with an oral predictive thermometer and the Caregiver thermometer. This validation study indicates a high level of agreement between the Caregiver and a calibrated oral predictive reference device thermometer, thus assuring accurate and reliable readings in children and adolescents age 0 to 18 years old.
Marketed by PositiveID’s Thermomedics subsidiary, Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.
“Caregiver is not only easier to use than most common thermometry devices, it is proven to be just as accurate and reliable,” stated William J. Caragol, Chairman and CEO of PositiveID. “We believe it also offers an improved patient experience since it is completely non-invasive, which is particularly important in pediatric populations.”
Data were collected in family medicine (clinic, hospital and home care) and pediatrics (outpatient, sick baby room, and hospital ward) departments at China Medical University Hospital (Taichung, Taiwan) over a one-year period.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the likelihood that since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16, 2016, and November 12, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 RedChip Companies Jon Cunningham (407) 644-4256